Published in final edited form as:

Anal Bioanal Chem. 2015 July ; 407(19): 5603–5613. doi:10.1007/s00216-015-8730-2.

Development and Validation of an UPLC-MS/MS Assay for Quantitative Analysis of the Ghrelin Receptor Inverse Agonist PF-5190457 in Human or Rat Plasma and Rat Brain

Mwlof Ghareeb¹, Lorenzo Leggio^{2,3}, Ayman El-Kattan⁴, and Fatemeh Akhlaghi¹

¹Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI 02881, USA

²Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, Laboratory of Clinical and Translational Studies, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA; and Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA

³Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University, Providence, RI 02903, USA

⁴ Pfizer Inc., 610 Main St, Cambridge, MA 02139, USA

Abstract

PF-5190457 is a ghrelin receptor inverse agonist that is currently undergoing clinical development for the treatment of alcoholism. Our aim was to develop and validate a simple and sensitive assay for quantitative analysis of PF-5190457 in human or rat plasma and rat brain using liquid chromatography-tandem mass spectrometry. The analyte and stable isotope internal standard were extracted from 50 μ L plasma or rat brain homogenate by protein precipitation using 0.1% formic acid in acetonitrile. Chromatography was carried on an Acquity UPLC BEH C18 (2.1 mm X 50 mm) with 1.7 μ m particle size and 130Å pore size. Flow rate was 0.5 mL/min and total chromatographic run time was 2.2 minutes. Mobile phase consisted of gradient mixture of water: acetonitrile 95:5% (v/v) containing 0.1% formic acid (Solvent A), and 100% acetonitrile containing 0.1% formic acid (Solvent B). Multiple reaction monitoring was carried out in positive electro-spray ionization mode using m/z 513.35 $\rightarrow$ 209.30 for PF-5190457 and m/z 518.47 $\rightarrow$ 214.43 for the internal standard. The recovery ranged from 102–118% with CV less than 6% for all matrices. The calibration curves for all matrices were linear over the studied concentration range ($R^2 = 0.998$, $n = 3$). Lower limit of quantification was 1 ng/mL in rat or human plasma and 0.75 ng/g in rat brain. Intra- and inter-run mean percent accuracy were between 85–115% and percent imprecision was $\leq 15\%$. The assays were successfully utilized to measure the concentration of PF-5190457 in pre-clinical and clinical pharmacology studies of the compound.

Keywords

alcoholism; bioanalytical methods; ghrelin; LC-MS/MS; PF-5190457; pharmacokinetics

Introduction

Ghrelin is a 28-amino acid peptide primarily produced by the endocrine X/A-like cells of the fundus mucosa of the stomach and acts as an endogenous ligand for the growth hormone secretagogue receptor (GHS-R1a). GHS-R1a is a G-protein coupled receptor that induces growth hormone (GH) release from the pituitary [1]. Ghrelin activates hypothalamic orexigenic neurons and inhibits anorectic neurons to induce hunger [2,3]. In humans, intravenous (IV) acetylated ghrelin administration increases appetite and food intake [4,5]. Moreover, ghrelin infusion can suppress glucose-dependent insulin secretion in rodents and humans resulting in insulin resistance [6,2]. Therefore, it is conceivable to believe that pharmacological modulation of ghrelin may be beneficial in regulating appetite and body weight or in treating type 2 diabetes mellitus.

Consistent with converging evidence illustrating that alcohol and food-seeking behaviors share common neural pathways [7,8], ghrelin signaling has been proposed as a potential novel pharmacological target for the treatment of alcoholism [9]. In mice, central ghrelin administration to reward nodes of the brain increased alcohol intake while central or peripheral administration of ghrelin receptor antagonists suppressed alcohol intake [10]. Furthermore, clinical studies from our team have shown that plasma concentrations of ghrelin were different in abstinent compared to active drinking alcohol-dependent individuals and correlated with alcohol craving [11]. Additionally, in a human laboratory setting, intravenous administration of 3 µg/kg ghrelin to alcohol-dependent, heavy-drinking individuals resulted in a significant acute increase in cue-induced alcohol craving [12]. Furthermore, there was a positive significant correlation between post-infusion blood ghrelin levels and increased alcohol craving [12].

Generally, it appears that GHS-1Ra antagonism can possibly increase satiety and does not only result in weight loss and improvement in glycemic control but it may also be helpful for treating alcoholism. PF-5190457 is a sensitive and specific ghrelin receptor inverse agonist that is orally bioavailable [13]. It is a member of a spiro-azetidino-piperidine series that was identified through high-throughput screening by Pfizer Pharmaceuticals. PF-5190457 (Mw=512), has a measured logD value of 1.5 at pH 7.4 and a topological polar surface area of 95. Pharmacokinetics studies in rats have shown a high volume of distribution and clearance and an almost 100% fraction absorption in portal vein cannulated rats [10]. Here, we report the development and validation of a sensitive, specific and robust assay for measurements of PF-5190457 in either human or rat plasma or in rat brain homogenate using an ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) technique.

Chemicals and reagents

PF-5190457 and the internal standard (IS) PF-06340740 (stable labeled isotope) were kindly donated by Pfizer. Optima™ LC/MS grade of acetonitrile, ammonium acetate, formic acid, and methanol were obtained from Fisher Scientific (Fair Lawn, NJ, USA). Deionized water was obtained using a Milli-Q Synthesis system fitted with a Q-Gard 2 Purification Pack (Millipore, Bedford, MA, USA). Drug-free K₂EDTA rat plasma or brain specimens were from Wistar rats (n=6) aged between 2 to 4 months and weighing between 300-500 grams (Bioreclamation IVT Inc., Westbury, NY, USA). Similarly, K₂EDTA human plasma from 6 subjects (3 male, 3 female) were obtained from Bioreclamation IVT Inc.

Instruments

Eppendorf 5810 refrigerated centrifuge from Micro and Nanotechnology (Urbana, IL, USA) was used to obtain supernatants. Acquity UPLC from Waters Corp (Milford, MA, USA) connected to Xevo TQ MS mass spectrometry (Waters Corp) was used to quantify PF-5190457 concentrations. Acquity UPLC system had a binary pump and was equipped with a built-in column heater. A 20 µL sample loop was used to deliver samples in partial loop injection mode. The system was controlled with MassLynx™ software (V 4.1) and data was processed using TargetLynx™ tool.

Chromatographic conditions

Chromatographic separation was carried out in an Acquity UPLC BEH C18 (2.1 mm X 50 mm) with 1.7 µm particle size and 130Å pore size analytical column (Waters Corp, Milford, MA). An Acquity UPLC BEH C18 pre-column was used to preserve the performance of the analytical column. The column was maintained at 55°C and an auto-sampler temperature was kept at 20°C. A gradient elution method was utilized with a mobile phase consisting of water: acetonitrile 95:5% (v/v) containing 0.1% formic acid (Solvent A), and 100% acetonitrile containing 0.1% formic acid (Solvent B). The mobile phase was delivered at 0.5 mL/min flow rate. Each chromatographic cycle started and maintained at 2% solvent (B) for 0.3 min and increased gradually to 98% over 0.7 min and maintained at this level until 1.8 min. To re-equilibrate the column for the next run, the proportion of solvent (B) was decreased within 0.1 min to 2% and kept constant until the end of the run at 2.2 min. To minimize detector contamination, a diversion valve was set to deliver the first 0.60 min and from 1.10 min until the end of each run to waste. The elution time for both analyte and IS was 0.83 min.

Mass spectrometry conditions

Multiple reaction monitoring (MRM) in positive electro-spray ionization (ESI) mode was used for detection and quantification of analytes and IS. The MS scan of infused PF-5190457 detected protonated molecules [M+H]⁺ (m/z= 513.61) with highest intensity, followed by sodium adduct (m/z= 535.61) [M+NA]⁺ as seen in **Figure 1**. Therefore, the protonated form was selected. Protonated precursors were fragmented into two compounds of similar intensity with m/z values of 127.21, and 209.30; a third compound (m/z =335.35) was fragmentized with 50% intensity compared to the first two fragments (**Figure 2**). The

two fragments with the highest m/z values were selected. MRM transitions were monitored (m/z , Q1→Q3); m/z , 513.35 → 209.30 transition was used for quantification while m/z , 513.35 → 335.35 transition was used as backup. m/z , 518.47 → 214.43 transition was selected for the internal standard. The proposed fragment formation of PF-5190457 is illustrated in **Figure 3**. All chemical structures were produced using ChemDraw version 14.0.0.117 from PerkinElmer Inc (Waltham, Massachusetts, USA). After automatically obtaining initial mass spectrometry parameters with IntelliStart tool, manual tuning of final parameters were performed to achieve the highest possible signal. Final mass spectrometry parameters were: capillary voltage = 0.30 kV, extractor voltage = 3 V, source temperature = 150°C, desolvation temperature = 650°C, desolvation gas flow = 400 L/Hr, and collision gas flow 0.15 mL/min. Cone voltages and collision energy were 32 and 38 for analytes with m/z , 513.35 → 209.30 transition and 32 and 18 for analytes with m/z , 513.35 → 335.35 transition, respectively; and 38, and 44 for the internal standard.

Preparation of standards, quality controls, and IS solutions

Sub-stock and working stock solutions of PF-5190457 and IS were prepared using 50% acetonitrile (ACN) and were stored at 4 °C. Standards and quality controls (QCs) samples were prepared by spiking rat or human plasma or rat brain homogenate to achieve desired PF-5190457 concentrations while keeping the organic solvent 5% of total volume.

Standard concentrations of PF-5190457 in rat brain homogenates before extraction were: 0.15, 0.30, 0.68, 2.40, 4.80, 9.60, 19.20, and 24.00 µg/L; QCs concentrations were 0.45, 3.00, and 18.00 µg/L for LQC, MQC, and HQC, respectively. The final standard and QCs concentrations in brain samples are shown in Tables 1 and 2.

Plasma standard concentrations before extraction were 1, 2, 10, 100, 250, 500, 800 and 1000 µg/L; QCs concentrations were 3, 200, 750 µg/L for LQC, MQC, and HQC, respectively. Working internal standard solutions (WIS) composed of 0.1% formic acid in ACN at concentrations of 5 and 10 µg/L were used as precipitating solvents for brain and plasma samples, respectively. The final standard and QCs concentrations in plasma samples are shown in Tables 1 and 2.

Protein precipitation and sample extraction

A. Rat brain samples

Brain segments from each rat were weighed individually and homogenized manually on ice using a glass tissue homogenizer with four-fold volume of de-ionized water (w:v) until a homogenous mixture was formed. One part brain homogenate of control blank, standards, QCs, and samples was extracted with two parts of 5 µg/L WIS in 1.5 mL Eppendorf tubes. Double blank samples were extracted with 100% ACN. After vortex mixing for 10 seconds, samples were centrifuged at 5000 xg for 5 min and 10 µL of supernatant was injected onto LCMS/MS.

B. Rat and human plasma samples

One part of rat or human plasma as control blank, standards, QCs, and plasma samples was mixed with four parts of 10 ng/mL WIS in a 1.5 mL microfuge tube. Double blank samples

were extracted with 100% ACN. After vortex mixing for 10 seconds, samples were centrifuged at 5000 xg for 5 min and 5µL of the supernatant was injected onto LC-MS/MS.

Assay validation

Standards and QCs

The method was validated in accordance with the current version of the Food and Drug Administration (FDA) guidance for industry bioanalytical method validation [14]. Calibration curves were constructed by plotting analyte/IS peak area ratio against the nominal concentration of analytes and fitted using a (1/x) weighting method. Accuracy and precision of the assay were determined using three different batches of brain or plasma that were spiked with working stock solutions to achieve standards and QCs concentrations (6 replicate) and extracted as described in the sample extraction section.

Sensitivity and selectivity

Lower limit of quantification (LLOQ) was determined by concentrations that had % bias $\pm 20\%$, coefficient of variation (CV) $\pm 20\%$ and signal to noise ratio (S/N) ≥ 10 . Acceptance criteria for QCs (LQC, MQC and HQC) was %bias $\pm 15\%$ and CV $\pm 15\%$. Selectivity assessed by inspecting the presence of noise or peaks at analyte and IS elution time on chromatograms represented blank brain or plasma samples (from 6 subjects).

Stability

Stability of PF-5190457 was investigated by quantifying QC1 and QC3 concentrations in three replicates. Freeze and thaw (three freeze and thaw cycles), bench-top, and short-term stability for up to one month were investigated. Auto-sampler stability was assessed, by re-injecting one of the validation batches kept in the auto-sampler for over 72 hours.

Matrix effect and recovery

Possible interference of matrix effect (ME) in brain and plasma samples was inspected visually through two ways. *First*, possible interference of matrices components was visually inspected on chromatograms generated using post-column infusion [15]. The test was performed by continuously infusing, after the column via a Tee connection, 98% ACN solution (represents the composition of mobile phase at elution time) containing PF-5190457 and IS at highest standards concentrations at a flow rate of 10 µL/min. Simultaneously, extracted blank brain samples, plasma samples, and neat solution (%50 ACN) were injected using the pre-established LC method. Chromatograms obtained from injecting blank brain or plasma samples were compared with a chromatogram that represented neat solution chromatograms for any signs of suppression and/or enhancement at analyte and IS elution region. *Second*, possible co-elution of analytes and IS with PL was also checked [16,17]. By including MRM transitions of abundant phospholipids (PL) in MS method, we were able to visually locate PL elution region at early stages of method development. Co-elution was avoided by manipulating liquid chromatography conditions and mobile phase gradients.

To determine recovery, two sets of QCs (from six subjects) were prepared. The first set of QCs was prepared in either brain or plasma and was extracted as prescribed in the samples

extraction section (pre-extracted matrices QCs). The second set was prepared by spiking extracted blank matrices with standard working solutions to achieve the same final concentration as the concentration in the first set. The percentage ratio of mean peak areas of pre-extracted samples to mean post-extracted spiked samples was used to calculate recovery.

Results and discussion

Sensitivity and selectivity

Brain concentration of analyte was expected to be very low compared to plasma. Therefore, mass spectrometry and chromatographic conditions were optimized using extracted brain samples to improve lower limit of quantification. Adequate sensitivity and selectivity were obtained using Acquity UPLC BEH C18 column. The final UPLC and mass spectrometry parameters were appropriate to set LLOQs at 0.75 and 1 µg/L for brain and plasma, respectively (**Figure 4**). Chromatograms obtained from pooled blank samples from six subjects and blank neat solutions (50% ACN) were visually inspected and compared for any peaks or noises at elution regions. No sign of interference was noticed. No carryover was detected when double blank samples were injected following the highest calibration concentration.

Curve fitting of the standard curve was comprised of 1/x weighted least squares linear regression. The average correlation coefficient (r^2) of the three validation batches was 0.999. The inter-run % bias and coefficient of variation (CV) were in the recommended limit of ± 20 for LLOQ and ± 15 for QCs (Table 2).

Stability

Bench top, freeze and thaw, auto-sampler, and short-term storage at $-80\text{ }^{\circ}\text{C}$ for up to four weeks were studied (Table 3). No stability problems were noticed and analytes were stable in extracted matrices for up to 72hrs.

Recovery and matrix effect

Samples processing and extraction procedures showed excellent recovery. The recovery ranged from 102-118% with CV less than 6% for all matrices (Table 3). Endogenous components in biological fluids may interfere and compete for ionization with the analytes of interest [15]. The ME could be either ionization suppression or enhancement, both of which can potentially compromise the integrity of the data [16]. A post-column infusion technique was utilized to examine possible interference of components present in matrices of interest. **Figure 5** shows a representative composite of PF-5190457 and IS traces obtained from post-column infusion at a concentration of 1 µg/mL overlaid on chromatograms obtained from injecting samples. An area of ionization suppression was seen around 0.25 minute in chromatogram from all matrices; slight ionization enhancement was also seen around 0.5 minute in all matrices (**Figure 5**). There was no sign of ionization suppression or enhancement at the retention time of analyte or IS.

The ME was investigated visually first by detecting elution regions of PL components of rat brain, rat plasma and human plasma. MRM of transitions of most common PLs [17,16] were

added to the mass spectrometry method. Mass transitions of PLs include m/z , $496 \rightarrow 184$, $520 \rightarrow 184$, $522 \rightarrow 184$, $524 \rightarrow 184$, $758 \rightarrow 184$, $782 \rightarrow 184$. As shown in **Figure 6**, the investigated PLs eluted far enough after analytes of interest in rat brain (A), rat plasma (B) and human plasma (C). It must be noted that PLs's that have m/z of 524 are more abundant in the brain when compared to rat and human plasma. In contrast, PLs's with m/z of 522 seem to be more abundant in rat and human plasma than in rat brain. Since the dilution factors (15 and 5 times for brain and plasma, respectively) and final water proportion in each final matrix extract was different, direct quantitative comparison was not possible.

Assay application

The assay was successfully utilized to measure compound concentrations in rat brains and plasma after administration of PF-5190457 as well as preliminary pharmacokinetic studies in human plasma conducted in the context of phase 1b study. Appropriate approvals were granted by the appropriate NIH Institutional Animal Care and Use Committee (IACUC) and the Institutional Review Board (IRB). **Figure 7** depicts a concentration-time profile of PF-5190457 in a representative human subject at steady-state after administration of 50 and 100 mg oral dose of PF-5190457.

Conclusion

This is the first reported analytical method for quantification of PF-5190457 in rat brain, rat plasma and human plasma. This LC-MS/MS method was developed and validated in accordance with the current FDA guideline and showed high sensitivity, selectivity and robustness. Simple extraction processes with excellent recovery and sufficient sample cleanliness was used. The method allowed us to examine the presence and describe relative components and elution behaviors of the investigated PLs species. The assays were successfully applied for quantification of PF-5190457 in both pre-clinical and clinical studies.

Acknowledgment

Authors would like to thank Professor Deyu Li for his help in elucidating the fragmentation pattern of PF-5190457.

Funding:

This work was supported by grant number 1UH2TR000963 (PIs: Akhlaghi and Leggio) from the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH); and by NIH intramural funding ZIA-AA000218 (PI: Leggio) jointly supported by the Division of Intramural Clinical and Biological Research of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the Intramural Research Program of the National Institute on Drug Abuse (NIDA).

ABBREVIATIONS

ACN	acetonitrile
CV	coefficient of variation
IS	internal standard
LLOQ	lower limit of quantification

ME	matrix effect
MeOH	methanol
MRM	multiple reaction monitoring
MS	mass spectrometry
Mw	molecular weight
PLs	phospholipids
QCs	Quality controls
UPLC-MS/MS	ultra performance liquid chromatography tandem mass spectrometry

References

1. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. *Nature*. 1999; 402(6762):656–660. doi:10.1038/45230. [PubMed: 10604470]
2. Tong J, Prigeon RL, Davis HW, Bidlingmaier M, Kahn SE, Cummings DE, Tschop MH, D'Alessio D. Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. *Diabetes*. 2010; 59(9):2145–2151. doi:10.2337/db10-0504. [PubMed: 20584998]
3. Solomon A, De Fanti BA, Martinez JA. Peripheral ghrelin participates in glucostatic feeding mechanisms and in the anorexigenic signalling mediated by CART and CRF neurons. *Nutritional neuroscience*. 2005; 8(5-6):287–295. doi:10.1080/10284150500502546. [PubMed: 16669599]
4. Druce MR, Wren AM, Park AJ, Milton JE, Patterson M, Frost G, Ghatei MA, Small C, Bloom SR. Ghrelin increases food intake in obese as well as lean subjects. *International journal of obesity*. 2005; 29(9):1130–1136. doi:10.1038/sj.ijo.0803001. [PubMed: 15917842]
5. Neary NM, Small CJ, Wren AM, Lee JL, Druce MR, Palmieri C, Frost GS, Ghatei MA, Coombes RC, Bloom SR. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. *The Journal of clinical endocrinology and metabolism*. 2004; 89(6):2832–2836. doi:10.1210/jc.2003-031768. [PubMed: 15181065]
6. Kirchner H, Tong J, Tschop MH, Pfluger PT. Ghrelin and PYY in the regulation of energy balance and metabolism: lessons from mouse mutants. *American journal of physiology Endocrinology and metabolism*. 2010; 298(5):E909–919. doi:10.1152/ajpendo.00191.2009. [PubMed: 20179246]
7. Volkow ND, Wang GJ, Tomasi D, Baler RD. The addictive dimensionality of obesity. *Biological psychiatry*. 2013; 73(9):811–818. doi:10.1016/j.biopsych.2012.12.020. [PubMed: 23374642]
8. Leggio L, Addolorato G, Cipitelli A, Jerlhag E, Kampov-Polevoy AB, Swift RM. Role of feeding-related pathways in alcohol dependence: A focus on sweet preference, NPY, and ghrelin. *Alcoholism, clinical and experimental research*. 2011; 35(2):194–202. doi:10.1111/j.1530-0277.2010.01334.x.
9. Leggio L. Role of the ghrelin system in alcoholism: Acting on the growth hormone secretagogue receptor to treat alcohol-related diseases. *Drug news & perspectives*. 2010; 23(3):157–166. doi:10.1358/dnp.2010.23.3.1429490. [PubMed: 20440417]
10. Jerlhag E, Eggecioglu E, Landgren S, Salome N, Heilig M, Moechars D, Datta R, Perrissoud D, Dickson SL, Engel JA. Requirement of central ghrelin signaling for alcohol reward. *Proceedings of the National Academy of Sciences of the United States of America*. 2009; 106(27):11318–11323. doi:10.1073/pnas.0812809106. [PubMed: 19564604]
11. Leggio L, Ferrulli A, Cardone S, Nesci A, Miceli A, Malandrino N, Capristo E, Canestrelli B, Monteleone P, Kenna GA, Swift RM, Addolorato G. Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving. *Addiction biology*. 2012; 17(2):452–464. doi:10.1111/j.1369-1600.2010.00308.x. [PubMed: 21392177]

12. Leggio L, Zywiak WH, Fricchione SR, Edwards SM, de la Monte SM, Swift RM, Kenna GA. Intravenous Ghrelin Administration Increases Alcohol Craving in Alcohol-Dependent Heavy Drinkers: A Preliminary Investigation. *Biological psychiatry*. 2014; 76(9):734–741. doi:10.1016/j.biopsych.2014.03.019. [PubMed: 24775991]
13. Bhattacharya SK, Andrews K, Beveridge R, Cameron KO, Chen C, Dunn M, Fernando D, Gao H, Hepworth D, Jackson VM, Khot V, Kong J, Kosa RE, Lapham K, Loria PM, Londregan AT, McClure KF, Orr ST, Patel J, Rose C, Saenz J, Stock IA, Storer G, VanVolkenburg M, Vrieze D, Wang G, Xiao J, Zhang Y. Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate. *ACS medicinal chemistry letters*. 2014; 5(5):474–479. doi:10.1021/ml400473x. [PubMed: 24900864]
14. US Department of Health and Human Services. Food and Drug Administration (FDA). Center for Drug Evaluation and Research (CDER). Guidance for Industry. Bioanalytical Method Validation. 2001
15. Dams R, Huestis MA, Lambert WE, Murphy CM. Matrix effect in bio-analysis of illicit drugs with LC-MS/MS: influence of ionization type, sample preparation, and biofluid. *J Am Soc Mass Spectrom*. 2003; 14(11):1290–1294. doi:10.1016/s1044-0305(03)00574-9. [PubMed: 14597119]
16. Chambers E, Wagrowski-Diehl DM, Lu Z, Mazzeo JR. Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2007; 852(1-2):22–34. doi:10.1016/j.jchromb.2006.12.030.
17. Zhang G, Wujcik CE. Overcoming ionization effects through chromatography: a case study for the ESI-LC-MS/MS quantitation of a hydrophobic therapeutic agent in human serum using a stable-label internal standard. *Journal of chromatography B, Analytical technologies in the biomedical and life sciences*. 2009; 877(22):2003–2010. doi:10.1016/j.jchromb.2009.05.031.

Figure 1.

Q1 scan of PF-5190457 shows the abundant adducts, $[M+H]^+$ and $[M+H_4]^+$.

Figure 2.

Q3 scan shows fragmentation pattern of PF-5190457 $[M+H]^+$ and intensity of daughter ions.

Figure 3.

Proposed fragmentation pathway of PF-5190457 $[M+H]^+$ into daughter ions with m/z of 209 and 335.

Figure 4.

A-F. Chromatograms of ghrelin antagonist (PF-5190457) (A, B, and C) and the internal standard) at LLO Q (D,E and F) and in rat brain, rat plasma and human plasma samples, respectively.

Figure 5.

A-C. A composite chromatogram of traces obtained from continues post-column infusion chromatograms of PF-5190457 (A, B, and C) and the internal standard (D, E, and F) overlaid on a chromatograms of injections of rat brain (left column), rat plasma (middle column) and human plasma (right column).

Figure 6.
A-C. Chromatograms depicting traces of phospholipids obtained from injecting pooled blank samples of rat brain (A), rat plasma (B) and human plasma (C). MRM transition of each individual phospholipids species is shown on the right side of the graph. The figures show the relative amount of PF-5190457 to PLs in each matrix.

Figure 7.
Concentration-time profiles of PF-5190457 in a representative study volunteer after ingestion of 50 and 100 mg doses of PF-5190457 by oral route.

Table 1

Summary of standards and calibration curve parameters from three individual runs

Matrix	Nominal conc. (µg/L)	STD 1	STD 2	STD 3	STD 4	STD 5	STD 6	STD 7	STD 8	R ²
Rat brain	Mean	0.83	1.47	4.04	11.86	23.47	44.59	97.84	117.85	0.9989
	SD	0.06	0.12	0.63	0.60	0.96	2.91	7.99	7.53	
	%Bias	10.20	-1.92	-10.33	-1.14	-2.20	-7.10	1.91	-1.79	
	CV	7.60	7.87	15.73	5.03	4.08	6.53	8.17	6.39	
Rat plasma	Nominal conc. (ng/mL)	1.00	2.00	10.00	100.00	250.00	500.00	800.00	1000.00	
	Mean	1.00	2.06	9.95	103.18	258.39	500.11	795.00	999.22	0.9999
	SD	0.10	0.27	1.11	12.63	33.70	23.88	35.87	33.04	
	%Bias	0.13	3.23	-0.47	3.18	3.36	0.02	-0.63	-0.08	
Human plasma	Nominal conc. (ng/mL)	1.00	2.00	10.00	100.00	250.00	500.00	800.00	1000.00	
	Mean	0.98	1.89	9.42	99.79	251.93	476.21	831.43	993.69	0.9989
	SD	0.09	0.25	3.89	11.29	14.59	30.72	38.45	28.31	
	%Bias	-2.12	-5.51	-5.81	-0.21	0.77	-4.76	3.93	-0.63	
	CV	9.05	12.99	41.25	11.32	5.79	6.45	4.62	2.85	

$n = 3$ (1 replicate for each of the three validation runs). %Bias calculated as $100 \times (\text{mean}-\text{nominal})/\text{nominal}$. CV calculated as $100 \times \text{std dev}/\text{mean}$.

Table 2

Summary of quality control samples from three individual runs.

Matrix	Nominal conc. (µg/L)	LLOQ	QC1	QC2	QC3
Rat brain	Nominal conc.	0.75	2.25	15.00	90.00
	Inter-run Mean	0.77	2.28	14.51	96.95
	Inter-run SD	0.10	0.24	1.14	5.47
	Inter-run %Bias	2.86	1.46	-3.25	7.72
	Inter-run CV	12.64	10.40	7.84	5.65
Rat plasma	Nominal conc. (ng/mL)	1.00	3.00	200.00	750.00
	Inter-run Mean	1.00	3.12	214.9	786.99
	Inter-run SD	0.17	0.35	18.30	57.02
	Inter-run %Bias	0.21	4.12	7.40	4.93
	Inter-run CV	16.99	11.17	8.50	7.24
Human plasma	Nominal conc. (ng/mL)	1.00	3.00	200.00	750.00
	Inter-run Mean	0.94	2.96	205.45	758.24
	Inter-run SD	0.15	0.40	13.99	83.22
	Inter-run %Bias	-5.67	-1.17	2.73	1.10
	Inter-run CV	15.55	13.63	6.81	10.97

$n = 18$ (6 replicates for each validation run). % Bias calculated as $100 \times (\text{mean} - \text{nominal}) / \text{nominal}$. CV calculated as $100 \times \text{std dev} / \text{mean}$.

Table 3

Results of stability studies

Matrix	QCs	Bench top 12 hrs	Freeze & thaw	72 hrs		Short term 1 weeks	Recovery %
				Auto-sampler			
Rat brain	QC1 (2.25) (ng/g)	Mean	2.3	2.2	2.4	2.5	102.0
		Bias %	2.2	-2.2	6.6	11.1	-
		CV	4.3	9.5	6.4	6.1	-1.2
	QC3 (90.0) (ng/g)	Mean	77.2	82.1	83.6	79.4	115.0
		Bias %	-14.2	-8.8	-7.1	-11.8	-
		CV	6.2	4.5	11.6	5.8	-1.4
Rat plasma	QC1 (3.0) (ng/mL)	Mean	3.4	3.1	3.0	3.1	117.0
		Bias %	14.4	3.3	1.2	3.3	-
		CV	11.0	8.5	11.5	5.6	-1.6
	QC3 (750) (ng/mL)	Mean	709.5	826.2	757.5	765.5	104.0
		Bias %	-5.4	10.2	1.0	2.1	-1.3
		CV	4.0	4.4	10.6	6.5	
Human plasma	QC1 (3.0) (ng/mL)	Mean	3.4	3.3	2.9	3.4	114.0
		Bias %	13.3	10.0	-3.2	13.3	-
		CV	6.1	6.1	9.4	7.8	-5.5
	QC3 (750) (ng/mL)	Mean	797.3	826.5	801.2	800.2	118.0
		Bias %	6.3	10.2	6.8	6.7	-
		CV	2.5	2.8	11.1	1.8	-1.4

$n = 3$. %Bias calculated as $100 \times (\text{mean-nominal})/\text{nominal}$. CV calculated as $100 \times \text{std dev}/\text{mean}$.